23 May 2013
Keywords: Pfizer, Bosulif, Bosutinib, Rare leukemia, Ph+, CML, USA, FDA
Article | 06 September 2012
In a third cancer drug approval in just over a year for drugs behemoth Pfizer (NYSE: PFE), the US Food ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 September 2012
22 May 2013
© 2013 thepharmaletter.com